Lancet Magazine Says Russian Sputnik V Covid-19 Vaccine Is Effective
The UK’s peer reviewed Lancet magazine, the mainstay of the medical services industry, has stated that patients involved in early tests of a Russian coronavirus vaccine developed antibodies with “no serious adverse events”. Russian researchers reported on two small trials, each involving 38 healthy adults aged between 18 and 60, who were given a two-part immunization. Each participant was given a dose of the first part of the vaccine and then given a booster with the second part 21 days later.
They were monitored over 42 days and all developed antibodies within the first three weeks.
The report said the data showed that the vaccine was “safe, well-tolerated, and does not cause serious adverse events in healthy adult volunteers”.
The trials were open label and not randomized, meaning there was no placebo and the participants knew they were receiving the vaccine and were not randomly assigned to different treatment groups.
Researchers underlined that larger and longer trials — including a placebo comparison — would be needed to establish the long-term safety and effectiveness of the vaccine for preventing Covid-19 infection.
The report said the 76 participants of these trials would be monitored up to 180 days, adding that a more rigorous phase 3 clinical trial was planned with the involvement of 40,000 volunteers “from different age and risk groups”.
“Showing safety will be crucial with Covid-19 vaccines, not only for vaccine acceptance but also for trust in vaccination broadly,” Naor Bar-Zeev of Johns Hopkins Bloomberg School of Public Health was quoted by the Lancet.
Russia has already completed the first week of inoculating its front-line citizens including health care workers and schoolteachers having rolled out the treatment from September 1st.
- Russian Covid Vaccine Manufacturers Looking At Shanghai Pharma Production
- Covid-19 Vaccines Under Development In Alternative Asia
Russia Briefing is written by Dezan Shira & Associates. The firm has 28 offices throughout Eurasia, including China, Russia, India, and the ASEAN nations, assisting foreign investors into the Eurasian region. Please contact Maria Kotova at firstname.lastname@example.org for Russian investment advisory or assistance with market intelligence, legal, tax and compliance issues throughout Asia.